CD133 (prominin-1) is a transmembrane glycoprotein expressed on the surface of normal and cancer stem cells (tumor-initiating cells), progenitor cells, rod photoreceptor cells and a variety of epithelial cells. Although CD133 is widely used as a marker of various somatic and putative cancer stem cells, its contribution to the fundamental properties of cancer cells, such as tumorigenesis and differentiation, remains to be elucidated. In the present report, we found that CD133 was expressed in several neuroblastoma (NB) cell lines/tumor samples. Intriguingly, CD133 repressed NB cell differentiation, for example neurite extension and the expression of differentiation marker proteins, and was decreased by several differentiation stimuli, but accelerated cell proliferation, anchorage-independent colony formation and in vivo tumor formation of NB cells. NB cell line and primary tumor-sphere experiments indicated that the molecular mechanism of CD133-related differentiation suppression in NB was in part dependent on neurotrophic receptor RET tyrosine kinase regulation. RET transcription was suppressed by CD133 in NB cells and glial cell linederived neurotrophic factor treatment failed to induce RET in CD133-expressing cells; RET overexpression rescued CD133-related inhibition of neurite elongation. Of note, CD133-related NB cell differentiation and RET repression were mainly dependent on p38MAPK and PI3K/Akt pathways. Furthermore, CD133 has a function in growth and RET expression in NB cell line-and primary tumor cell-derived tumor spheres. To the best of our knowledge, this is the first report of the function of CD133 in cancer cells and our findings may be applied to improve differentiation induction therapy for NB patients.
Introduction
CD133 (AC133; human prominin-1) belongs to a family of cell-surface glycoproteins harboring five transmembrane domains (Corbeil et al., 2001 ) and was originally found as a hematopoietic stem cell marker (Yin et al., 1997) . CD133 was subsequently shown to be expressed by a number of progenitor cells, including those of the epithelium, where it is expressed on the apical surface . Previously, it was found that CD133-expressing cells in brain tumors have the capacity for unlimited self-renewal, as well as the ability, in small numbers, to initiate tumor formation and progression in immuno-deficient mice (Singh et al., 2004) , suggesting that CD133-expressing cells satisfy the important criteria required for tumor-initiating cells (TICs) (Reya et al., 2001; Jordan et al., 2006) . Using similar methods, CD133 has recently been designated as a marker associated with TICs in the colon (O'Brien et al., 2007; Ricci-Vitiani et al., 2007) , pancreatic (Olempska et al., 2007) , liver (Yin et al., 2007) , skin (Monzani et al., 2007) and prostate (Collins et al., 2005; Miki et al., 2007) cancers. Maw et al. (2000) reported homozygosity for a 1-bp deletion (1878delG) in exon 16 of the CD133 gene predicted to cause a frameshift at codon 614 and a prematurely truncated protein lacking about half of the second extracellular loop, the final membrane-spanning segment and the cytoplasmic-C-terminal domain; this missense mutation caused retinal degeneration in four affected members of a consanguineous Indian family. This finding was further confirmed by an article describing that loss of Prom-1 in genetically modified mouse results in the progressive degeneration of mature photoreceptors with complete loss of vision (Zacchigna et al., 2009) ; however, to the best of our knowledge, no reports have studied the function of CD133 in tumorigenesis.
Neuroblastoma (NB) is the most common pediatric solid malignant tumor derived from the sympathetic nervous system. Unlike the many childhood malignancies for which survival has been improved by recent therapies, high-risk NB is still one of the most difficult tumors to cure, with only 30% long-term survival despite intensive multimodal therapy (Maris et al., 2007) . The clinical presentation and treatment response of advanced NB, which results in relapse and a refractory state after a good responsive to the initial chemotherapy, suggest that TICs likely exist in NB tumors. A previous report indicated the isolation and characterization of putative TICs using primary-sphere formation with tumors and bone marrow metastases from NB patients, although CD133 expression was not detected in a bone marrow-derived high-risk NB tumorsphere sample (Hansford et al., 2007) . On the other hand, it was reported that sub-cloned NB cells (designated 'intermediate type'), which have a significantly more malignant phenotype, with four-to fivefold greater plating efficiencies in soft agar and sixfold higher tumorigenicity in athymic mice, expressed high amounts of CD133 mRNA compared with less malignant subclones (Walton et al., 2004) ; therefore, the function of CD133 in NB tumorigenesis and aggressiveness remains unresolved.
Previous reports about CD133 expression in NB and its function as a stem cell marker in several tumors prompted us to study the function of CD133 in NB cells (Walton et al., 2004; Hansford et al., 2007) . Our results clearly indicated that CD133 also seems to regulate cell proliferation and tumorigenesis in NB cells. Importantly, CD133 represses NB cell differentiation and is decreased by several differentiation stimulators. We studied the molecular mechanism of CD133-related differentiation inhibition in NB cells and found that it was in part dependent on RET tyrosine kinase receptor regulation via signal pathway modification. Furthermore, CD133 is expressed in NB cell spheres and has a function in sphere growth and RET regulation.
In specific malignancies, for example NB and acute promyelocytic leukemia, differentiation induction therapy using retinoic acid is clearly effective. In vitro experiments indicated that all-trans-retinoic acid (ATRA) treatment induced morphological and biochemical differentiation in these cancer cells, suggesting that the induced differentiation seems to repress the tumorigenic activity of cancer cells (Brodeur et al., 2000; Weinberg, 2006) . Together, CD133 may regulate NB tumorigenesis and proliferation by preventing differentiation.
Results
CD133 has a function in NB cell proliferation First, we checked the expression of CD133 in NB cell lines and found its expression in 7 out of 20 (53%) cell lines ( Figure 3d and Supplementary Figure 1S) . A high level of cell-surface expression of CD133 was detected in TGW and SK-N-DZ cells, and modest expression was found in IMR32 ( Figure 1a ; Supplementary Figure  1Sa) . Next, we knocked down CD133 in highly expressing NB cells and analyzed the knockdowninduced phenotype. Figure 1b shows that infection of shRNA-reduced CD133 mRNA and protein and CD133 knockdown in TGW cells effectively resulted in significant growth retardation. Inhibition of cell proliferation by CD133 small-interference RNA was also observed in SK-N-DZ cells (Supplementary Figure  S1) . Furthermore, stable knockdown of CD133 in TGW cells suppressed cell proliferation under anchorageindependent conditions (Figure 1c ). To test tumorigenicity in vivo, CD133-silenced TGW cells were injected subcutaneously into nude mice. Mock shRNA lentivirus-infected cells formed large tumors within 9 days post-injection; CD133 shRNA lentivirus-infected cells formed very small tumors ( Figure 1d ). Next, we examined the effect of CD133 on NB cell proliferation (Supplementary Figure 2S) . CD133 was successfully expressed in SH-SY5Y cells by lentivirus. The proliferation rate of CD133-expressing SH-SY5Y cells was 2-2.5-fold greater than mock cells. Moreover, a soft agar colony formation assay showed that CD133-expressing cells formed more and bigger colonies than mock-control cells.
CD133 knockdown induces NB differentiation
In NB cells, differentiation into a neuronal phenotype is induced when cells are treated with several stimulations. Glial cell line-derived neurotrophic factor (GDNF) induced neurite outgrowth in TGW cells (Figure 2a , center). In CD133 knocked-down TGW cells, neurite formation was observed even under normal culture conditions (Figure 2a, KD) . We scored cells with neurite length longer than the cell body diameter as neurite positive (Figure 2b ). CD133 knocked-down cells showed intensified neurite extensions when compared with mock cells. Mock-infected and CD133 knocked-down cells were collected at the end of the experiment, and mRNA was extracted and subjected to RT-PCR (Figure 2c ). With GAP43/neurofilament (NF) 68 as neuronal differentiation markers, these expressions were constitutively upregulated in CD133 knocked-down cells. Along with differentiation induced by treatment with ATRA or phorbol-12-myristate-13-acetate (TPA) in parental TGW cells, CD133 expression was suppressed at both protein and mRNA levels (Supplementary Figure 3S) . These results indicated that CD133 may suppress the differentiation of NB cells.
CD133 regulates RET expression in NB cells
To identify the mechanism of CD133-related cellular differentiation, we studied the expression of several neurotrophic receptors and RET receptors because they are the important signal transduction pathway molecules, which have important functions in sympathetic nerve and NB cell differentiation (Kaplan et al., 1993; Klein, 1994; D'Alessio et al., 1995; Enomoto et al., 2001) . We introduced CD133 cDNA into several NB cell lines (Figure 3a) , and checked the effect of CD133 overexpression on RET expression using a primer pair recognizing all RET isoforms, RET51, RET9 and RET43, formed by alternative splicing of C-terminal exon cassettes (Myers et al., 1995; Enomoto et al., 2000) . Intriguingly, in RET and all RET isoforms, transcriptions were suppressed in CD133-overexpressing NB cells (RET reduction was 1.3-3.8-fold by qPCR); however, the effects of CD133 on TrkA/B/C, p75NGFR and GDNF expressions did not show a specific tendency. CD133 knockdown clearly increased RET mRNA (RET induction was 2.5-3.0-fold by qPCR). CD133-mediated RET downregulation was also observed at the protein level ( Figure 3b ). Furthermore, CD133 expression in primary NB spheres resulted in transcriptional suppression of RET (Figure 3c ). These results suggest that CD133 suppresses RET gene transcription in NB cells.
To study the expression pattern of CD133 and RET mRNA in human NBs, we performed semi-quantitative RT-PCR. CD133 was expressed in 7 of 20 NB cell lines tested (Figure 3d ), and only 1 NB cell line was RET positive in the 7 cell lines. We further studied CD133 and RET expression in unfavorable patient-derived tumors (stages 3 and 4, TrkA(À), MYCN amplified). Again, RET expression was profoundly repressed in CD133-expressing NB tumors ( Figure 3e ). Finally, we studied the transcriptional activity of RET promoter in CD133-expressing cells. RET promoter reporter-derived luciferase activity was significantly suppressed in CD133-expressing cells (Figure 3e ).
CD133 regulates NB cell differentiation in a RET-dependent manner
We investigated the biological effects of CD133 overexpression on RET downregulation in SH-SY5Y cells. Significant neurite outgrowth was observed when mockinfected cells were stimulated with GDNF (Figure 4a ). At the same time, no obvious difference was observed between mock-and GDNF-treated CD133-expressing cells. These results implied that CD133 overexpression inhibited NB cell differentiation.
We examined the effect of the co-expression of CD133 and RET (RET9) on SH-SY5Y cells. RET-expressing lentivirus was co-infected into stably CD133-expressing SH-SY5Y cells. Ten days after infection, ectopic RET and CD133 expressions were observed both at protein Semi-quantitative RT-PCR analyses were performed with CD133-modified NBs using specific primers against each RET isoform, Trk families, GFRa-1/2 and GDNF. GAPDH was used as a loading control. Expression level of RET (pan) was analyzed by qPCR. In qPCR, relative RET values were normalized by GAPDH. Data are representative results of at least three independent experiments. (b) CD133-expressing SH-SY5Y or CD133 knocked-down TGW cell lysates were subjected to western blotting for CD133 and pan-RET expression. Pan-RET antibody detected two bands corresponding to RET isoforms (arrows). (c) Primary sphere from a stage 4 NB patient was infected with mock or CD133-expressing lentivirus. Five days after infection, RNA was extracted for semiquantitative RT-PCR of CD133/RET and qPCR of RET. 
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H Takenobu et al and mRNA levels ( Figure 4b and data not shown). As seen in Figure 4a , GDNF significantly induced neurite outgrowth of CD133/RET co-expressing SH-SY5Y cells. CD133 single-infected cells did not respond to GDNF, suggesting that the response was dependent on RET receptor expression. However, the expression of neuronal cell differentiation markers induced by GDNF was not recovered by RET in CD133-expressing cells (Figure 4b ). These findings indicated that CD133 inhibits GDNF-promoted neuronal differentiation via not only by RET but also by the other signal pathways.
CD133 regulates RET expression and NB cell differentiation by modification of signaling pathways To identify the mechanism of RET downregulation in CD133-expressing cells, we studied the signaling molecule status in CD133 knocked-down cells (Figure 4c ) and found a strong suppression of Akt (473S, 308T) and p38MAPK phosphorylation, but not ERK1/2 in both TGW and SK-N-DZ cells. To confirm the Akt and p38MAPK phosphorylation status caused by CD133 downregulation, we treated TGW cells with kinase inhibitors. MEK1 inhibitor (PD98059, PD), p38MAPK inhibitor (SB203580, SB) and PI3K inhibitor (LY294002, LY) induced neurite elongation in NB cells, and SB and LY were more effective for neurite elongation than PD. RET induction by kinase inhibitors was correlated with neurite elongation; however, differentiation markers NF68 and GAP43 were significantly induced by SB treatment. These results suggest that downregulation of p38MAPK and PI3K/Akt pathways has a function in CD133-related neurite elongation and differentiation marker expression is affected mainly by the p38MAPK pathway.
CD133 has a function in tumor-sphere growth and cell survival It was previously reported that NB TICs were accumulated in NB spheres in serum-free media (SFM) (Hansford et al., 2007) . These observations prompted us to study the function of CD133 in tumor-sphere formation of NB cells. In IMR32 cells, only a small fraction of cells expressed CD133 (Supplementary Figure 1Sa) . IMR32 cells were cultured in SFM with epidermal growth factor and fibroblast growth factor for a week, and sphere formation, upregulation of CD133 (11.8-fold induction) and suppression of RET (2.8-fold reduction) were observed ( Figure 5a ). In primary NB cells from bone marrow metastasis, and/or RET9 co-expressing SH-SY5Y cells were treated with GDNF (50 ng/ml) for 72 h. Cells were scored for the presence of neurites longer than one cell diameter after GDNF treatment. (b) CD133 and/ or RET9 co-infected SH-SY5Y cells were cultured with or without GDNF treatment. Semi-quantitative RT-PCR analyses of CD133, GAP43, RET and GAPDH were performed. (c) The levels of phosphoAkt (p-Akt(473S) and p-Akt(308 T)), total-Akt, phospho-p38MAPK (p-p38), total-p38MAPK, phospho-ERK (p-ERK), total-ERK and tubulin were analyzed by western blot analysis. (d) TGW cells were cultured with DMSO (mock, 0.1%), PD98059 (PD, 5 mM), SB203580 (SB, 5 mM), LY294002 (LY, 5 mM), GDNF (50 ng/ml) or ATRA (5 mM) for 96 h. Cells were scored for the presence of neurite longer than one cell diameter after treatments. Semi-quantitative RT-PCR analysis of RET/NF68/GAP43/GAPDH, and qPCR of RET were performed.
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the upregulation of CD133 (1.4-fold induction) and downregulation of RET receptors (5.9-fold reduction) were found in SFM medium, but not in the medium with 10% fetal bovine serum ( Figure 5b ). Next, we introduced CD133 into IMR32 cells by lentivirus infection, and after 5-week culture in SFM, we found that CD133-expressing cells formed many more large spheres than mock cells (Figure 5c ). Moreover, CD133-expressing spheres made from IMR32 and primary NB cells contained many more living cells than the mock control (Figure 5d ), suggesting that CD133 promotes NB cell survival in tumor-sphere formation.
Discussion
Increasing evidence highlights the function of CD133 as a marker of CSCs in various human tumors; however, its function in tumorigenesis remains to be elucidated by molecular biology experiments. In this study, CD133-knockdown experiments indicated that CD133 represses differentiation in NB cells; CD133 was clearly decreased by differentiation-inducing stimulation, for example ATRA and TPA treatments. Brodeur et al. (2000) indicated that neurotrophic factors and their receptors have a significant function in NB behavior and the potential to send intracellular signals into the nucleus to produce neuronal differentiation in the normal sympathetic nerve system. Among the NB cell differentiationrelated neurotrophic receptors, RET transcription was regulated by CD133 in NB cell lines. The expression of CD133 effectively inhibited NB cell differentiation (neurite extension and differentiation markers). Furthermore, RET expression partly rescued the CD133-related inhibition of differentiation. These findings suggest that CD133-mediated RET suppression has a considerable function in NB cell differentiation. Regarding the function of RET in NB differentiation, Peterson and Bogenmann (2004) suggested that RET receptor activation inhibits cell cycle progression and enhances responsiveness to NGF; thus, NB cell differentiation requires the collaboration of functional RET and TrkA signal pathways; they also reported that GDNF treatment induced RET transcription in NB cells. Intriguingly, our results indicate that CD133 expression effectively suppressed RET mRNA in NB cells and CD133 knockdown induced NB cell differentiation, suggesting that suppression of CD133 by small-interference RNA administration will increase RET transcription in CD133-expressing NB tumors and may be useful in differentiation induction therapy for resistantand relapsed-NB tumors. In addition, transcriptional suppression of CD133 could be useful to induce differentiation in NB cells; however, the exact mechanism of transcriptional regulation of CD133 has not been clarified. Although seven CD133 mRNA isoforms controlled by five alternative promoters were reported previously (Shmelkov et al., 2004) , the promoter activities of these isoforms were studied only by pGL3-enhancer vector, suggesting the existence of other cis-elements in the CD133 locus. 
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Several studies have been reported to elucidate the molecular mechanism and signaling pathways that regulate the behavior of CD133-expressing cancer cells. Nikolova et al. (2007) reported that WNT-conditional media had effects on the proliferation and differentiation of cord blood-derived CD133-positive cells, and Fan et al. (2006) showed that Notch signal inhibition by GSI-18 reduced the CD133-positive fraction in brain tumor cells. Regarding the analysis of the intracellular signaling pathway related to the CD133 function, one report suggested the significance of the Akt/PKB pathway in the expression of survival proteins, phosphor-Bad and Bcl-2 in CD133-positive hepatocellular carcinoma cell survival (Ma et al., 2007) . In our study, CD133-knockdown experiments indicated that CD133-related RET repression and NB cell differentiation were caused by signal pathway activation, for example p38MAPK and PI3K/Akt pathways. To support this observation, treatment with kinase inhibitors showed a correlation between neurite elongation and RET induction in NB cells, and that differentiation marker protein induction was mainly dependent on the p38MAPK pathway. These findings suggest that CD133 prevents NB cell differentiation via signal transduction pathways. To the best of our knowledge, this is the first report of CD133-related signal pathway modification resulting in cell differentiation. As CD133 is a membranous protein on stem cells and cancer stem cells, it is possible that CD133 affects membranous receptor functions and the downstream signal pathways. In addition, Boivin et al. (2009) reported the phosphorylation of CD133-cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Site-directed mutagenesis of these tyrosine residues in CD133 will provide important information for CD133 functions in our experimental system using NB cells.
Materials and methods

Cell culture and reagents
Human NB cell lines were obtained from official cell banks (RIKEN Cell Bank, Tsukuba, Japan and ATCC, Manassas, VA, USA) and cultured in high-glucose DMEM (SigmaAldrich, St Louis, MO, USA) or RPMI1640 (Wako, Osaka, Japan) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 50 mg/ml penicillin/ streptomycin (Sigma-Aldrich) in an incubator with humidified air at 37 1C with 5% CO 2 . NB cell lines subjected to molecular biology and biochemistry experiments were MYCN single-copy SH-SY5Y cells and MYCN-amplified TGW, SK-N-DZ and IMR32 cells. GDNF was obtained from Invitrogen. ATRA was from Sigma-Aldrich. Phorbol-12-myristate-13-acetate (TPA) was from Nacalai Tesque (Kyoto, Japan). LY294002 was from Cell Signaling Technology (Beverly, MA, USA). PD98059 and SB203580 were from Calbiochem (San Diego, CA, USA).
Fluorescence-activated cell sorting analysis NB cell lines growing in the log phase were enzymatically removed from 10 cm diameter culture dishes, washed with cold PBS and treated with biotinylated AC133 (CD133/1) monoclonal antibodies (Miltenyi Biotec, Auburn, CA, USA) or control IgG2A (eBioscience, San Diego, CA, USA) for 15 min at 4 1C. The primary antibody was removed, and then the cells were washed twice with ice-cold PBS containing 0.1% BSA, and a 1:200 dilution of phycoerythrin-labeled streptavidin (eBioscience) added for 15 min at 4 1C. After washing, flow cytometry was performed using a fluorescence-activated cell sorting Caliber (BD, San Jose, CA, USA).
Knockdown of CD133
For RNAi experiments, predesigned, double-stranded SMARTpool small-interference RNA targeting human CD133 (prominin-1) was purchased from Dharmacon (Lafayette, CO, USA) and Silencer Negative Control small-interference RNA #1 was purchased from Ambion (Austin, TX, USA). 
Cloning of human CD133 cDNA
The human CD133 cDNA (RefSeq NM_006017) was cloned from human colon cancer cell line Caco-2 mRNA by RT-PCR using specific primer sets described in Supplementary Table 1S . CD133 cDNA fragment was sub-cloned into a lentiviral-based vector (pHR-SIN-CSGW) (Hasegawa et al., 2006) .
Western blot analysis
The cells were lysed in buffer containing 5 mM EDTA, 2 mM Tris-HCl (pH 7.5), 10 mM b-glycerophosphate, 5 mg/ml aprotinin, 2 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , a protease inhibitor cocktail (Nacalai Tesque) and 1% SDS. Western blot analysis was performed as reported previously (Kurata et al., 2008) . For CD133 detection, we used AC133 monoclonal antibody. Anti-RET (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-phospho-and total Akt, p38, ERK (Cell Signaling Technology) and anti-tubulin antibody from Lab Vision (Fremont, CA, USA) were also used.
Semi-quantitative RT-PCR
Semi-quantitative RT-PCR analysis was as described previously (Kurata et al., 2008) . Total cellular RNA for preparing RT-PCR templates was extracted using ISOGEN (Nippon Gene KK, Tokyo, Japan). The cDNA was synthesized from 1 mg total RNA and then subjected to PCR. Primer sequences are described in Supplementary Table 1S . RT-PCR results are representative of at least three independent experiments.
qPCR analysis
The qPCR analysis was performed as described previously (Ochiai et al., 2010) . The primers for qPCR were designed and synthesized to produce 50-150 bp products. The primer sequence is listed in Supplementary Table 1S . The results were representative of at least three independent experiments.
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Cell proliferation and soft agar assay Cells were seeded into 96-well plates (750 per well) in culture medium containing 10% fetal bovine serum. Every 24 h, cell viability was determined by water-soluble tetrazolium salt (WST-8) assay using Counting kit-8 (Dojindo, Kumamoto, Japan) according to the manufacturer's protocol. For soft agar assay, 2 Â 10 3 cells of stable infectants TGW or SH-SY5Y cells were seeded in soft agar as described previously (Aoyama et al., 2005) . Viable colonies were stained with 0.05 mg/ml MTT.
Tumor formation in nude mice
For tumor formation, 6-week-old female athymic BALB/c AJcl nu/nu mice (CLEA Japan, Shizuoka, Japan) were injected into the femur with 1 Â 10 7 TGW cells as described previously (Aoyama et al., 2005) . The handling of animals was in accordance with the guidelines of Chiba Cancer Center Research Institute.
Patients and tumor specimens
The 12 tumor specimens used in this study were kindly provided by various institutions and hospitals in Japan. Informed consent was obtained at each institution or hospital. All tumors were diagnosed clinically as well as pathologically as NB and staged according to the International NB Staging System criteria. The patients were treated by standard chemotherapy protocols as described previously (Kaneko et al., 2002; Iehara et al., 2006) . MYCN copy number, TrkA mRNA expression levels and DNA index were measured as reported previously (Ohira et al., 2003) . This study was approved by the Institutional Review Board of Chiba Cancer Center.
Subcloning of human RET (RET9)
Human RET9 (Crowder et al., 2004) full-length cDNA was a kind gift from Dr Hideki Enomoto (RIKEN Center for Developmental Biology, Hyogo, Japan). RET9 cDNA fragment (3.4 kb) was sub-cloned into the NotI site of CSII-CMV-MCS-IRES2-Bsd vector, which had been altered to accept the XbaI and HindIII ends.
Cloning of human RET promoter
Human RET promoter 1.5 kb (À919 to þ 550, position þ 1 is the transcription start site determined in a previous report (Itoh et al., 1992) ) was amplified from human genomic DNA using Platinum Pfx polymerase (Invitrogen) with primers (described in Supplementary Table 1S) by PCR amplification and sub-cloned into pGEM-T easy vector (Promega, Southampton, UK). The RET 5 0 -flanking sequence from À453 to þ 227 was sub-cloned into the EcoRV site of pGL4.17 reporter vector (Promega).
Sphere culture of NB cells
The preparation of primary NB cells from stage 4 patients' bone marrow was described previously (Nakanishi et al., 2007) . Dissociated primary NB cells or IMR32 cells were cultured in SFM (DMEM-F12, 1:1 (Wako), 50 mg/ml penicillin/streptomycin, 2% B27 supplement (Invitrogen), 20 ng/ml epidermal growth factor (Sigma-Aldrich) and 20 ng/ml fibroblast growth factor basic (Invitrogen)). Half of the medium was replaced with fresh culture medium every 7 days. IMR32 cells and primary NB cells were seeded in 96-well (400 per well) or six-well (1 Â 10 5 per well) and six-well (1.7 Â 10 5 per well) plates, respectively. Spheres were counted and measured under a microscope with an eyepiece micrometer. Five-week cultured IMR32 or 2-month cultured primary NB spheres were dissociated by Accumax (Innovative Cell Technologies, San Diego, CA, USA) according to the manufacturer's protocol. Living cells were counted based on morphological criteria and trypan blue staining.
